Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study

Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long‐Term Follow‐Up: Results From the NODE‐302 Study

Background Self‐administration of investigational intranasal L‐type calcium channel blocker etripamil during paroxysmal supraventricular tachycardia (PSVT) appeared safe and well‐tolerated in the phase 3 NODE‐301 (Multi‐Centre, Randomized, Double‐Blind, Placebo‐Controlled, Efficacy, and Safety Study...

Full description

Bibliographic Details
Main Authors: James E. Ip, Benoit Coutu, Matthew T. Bennett, A. Shekhar Pandey, Bruce S. Stambler, Philip Sager, Michael Chen, Silvia Shardonofsky, Francis Plat, A. John Camm
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
etripamil
NODE‐302
paroxysmal supraventricular tachycardia
self‐administered
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.028227

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.028227

Similar Items